Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
NCT06540963Phase 2Recruiting
- Start
- Dec 2024
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tipifarnib in neuroblastoma (2 arms). Primary endpoint: Overall Response Rate at 6 months. Started Dec 2024; status: recruiting.
02
Drugs
tipifarnib
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT06540963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06540963.